Aegerion in the News

The following is a selection of news stories and events in which Aegerion is featured.

Xconomy: Two Years After Rising from Ashes, Aegerion Preps for Drug Debut
When Marc Beer joined Cambridge, MA-based Aegerion Pharmaceuticals (NASDAQ:AEGR) as CEO in August 2010, the company was $4 million in debt, nearly insolvent, and “not following a clear path,” he says. By October of that year, Beer, a former Genzyme executive, had worked out a development plan for Aegerion’s cholesterol-lowering drug and taken the company public, raising $48.8 million.
BioWorld: After FDA Accepts Lomitapide NDA, Aegerion Seeks $47.3M
A month after the FDA accepted its new drug application (NDA) for lead compound lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in patients with homozygous familial hypercholesteremia (HoFH) and familial chylomicronemia (FC), Aegerion Pharmaceuticals Inc. priced an underwritten public offering of 3.4 million shares of common stock at $14.75 each, seeking to raise approximately $47.3 million.